Who are continuous pivotal βL-AB's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Unasyn, Pipracil, Piperacillin And Tazobactam, Ascabin, ampicillin/clavulanate, Merrem.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/continuous-pivotal-l-ab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

continuous pivotal βL-AB — Competitive Intelligence Brief

continuous pivotal βL-AB (continuous pivotal βL-AB) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: beta-lactamase inhibitor. Area: Infectious Diseases.

marketed beta-lactamase inhibitor beta-lactamase Infectious Diseases Small molecule Live · refreshed every 30 min

Target snapshot

continuous pivotal βL-AB (continuous pivotal βL-AB) — Assistance Publique - Hôpitaux de Paris. βL-AB is a beta-lactamase inhibitor that works by inhibiting the bacterial enzyme beta-lactamase, which breaks down beta-lactam antibiotics.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
continuous pivotal βL-AB TARGET	continuous pivotal βL-AB	Assistance Publique - Hôpitaux de Paris	marketed	beta-lactamase inhibitor	beta-lactamase
Unasyn	SULBACTAM	Pfizer	marketed	beta Lactamase Inhibitor	Serine beta-lactamase-like protein LACTB, mitochondrial	1986-01-01
Pipracil	Piperacillin Sodium	Pfizer Inc.	marketed	Penicillin-class antibacterial with beta-lactamase inhibitor	Beta-lactamase producing bacteria	1981-01-01
Piperacillin And Tazobactam	Piperacillin Sodium	Pfizer	marketed	Penicillin-class antibacterial with beta-lactamase inhibitor	Bacterial cell wall; beta-lactamase enzyme	1981-01-01
Ascabin	BENZYL BENZOATE	Lannett	marketed	benzyl benzoate	Beta-lactamase, Hormone-sensitive lipase	1976-01-01
ampicillin/clavulanate	ampicillin/clavulanate	Phoenix Children's Hospital	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); bacterial beta-lactamases
Merrem	Merrem	National Institutes of Health Clinical Center (CC)	marketed		Beta-lactamase, Beta-lactamase NDM-1, Beta-lactamase class B VIM-2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2033-04-02 — Unasyn · 9623014 · US
2033-04-02 — Unasyn · 9309245 · US
2035-11-17 — Unasyn · 10376499 · US
2035-11-17 — Unasyn · 9968593 · US

Sponsor landscape (beta-lactamase inhibitor class)

Assistance Publique - Hôpitaux de Paris · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). continuous pivotal βL-AB — Competitive Intelligence Brief. https://druglandscape.com/ci/continuous-pivotal-l-ab. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab